Age and shock severity predict mortality in cardiac intensive care unit patients with and without heart failure

Mitchell Padkins¹, Thomas Breen¹, Nandan Anavekar², Sean van Diepen³, Timothy D. Henry⁴, David A. Baran⁵, Gregory W. Barsness², Kianoush Kashani⁶,⁷, David R. Holmes Jr² and Jacob C. Jentzer²,⁶* 

¹Mayo Clinic School of Graduate Medical Education, Mayo Clinic, Rochester, MN, USA; ²Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; ³Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada; ⁴The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, OH, USA; ⁵Advanced Heart Failure Center and Eastern Virginia Medical School, Sentara Heart Hospital, Norfolk, VA, USA; ⁶Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA; ⁷Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract

Aims Age is an important risk factor for mortality among patients with cardiogenic shock and heart failure (HF). We sought to assess the extent to which age modified the performance of the Society for Cardiovascular Angiography and Interventions (SCAI) shock stage for in-hospital and 1 year mortality in cardiac intensive care unit (CICU) patients with and without HF.

Methods and results We retrospectively reviewed unique admissions to the Mayo Clinic CICU during 2007–2015 and stratified patients by age and SCAI shock stage. The association between age and in-hospital mortality was analysed using multivariable logistic regression, and 1 year mortality was analysed using Cox proportional hazards analysis, both in the entire cohort and among patients with an admission diagnosis of HF or acute coronary syndrome (ACS). The final study population included 10 004 unique patients with a mean age of 67 ± 15 years, including 46.1% with HF and 43.1% with ACS. Older patients more frequently had HF and had more extensive co-morbidities, higher illness severity, more organ failure, and differential use of critical care therapies. The percentage of patients with SCAI shock stages A, B, C, D, and E were 46%, 30%, 16%, 7%, and 1%, respectively. Patients with HF were older, had greater severity of illness and higher SCAI shock stage, and had higher rates of death at all time points. In-hospital mortality occurred in 908 (9%) patients, including 549 (12%) patients with HF (61% of all hospital deaths). Age was independently associated with hospital mortality (adjusted odds ratio per 10 years 1.3, 95% confidence interval 1.2–1.4, P < 0.001) and 1 year mortality (adjusted hazard ratio per 10 years 1.2, 95% confidence interval 1.2–1.3, P < 0.001) in the overall cohort. The associations of age with both hospital mortality (adjusted odds ratio 1.6 vs. 1.3 per 10 years older) and 1 year mortality (adjusted hazard ratio 1.5 vs. 1.3 per 10 years older) were higher for patients with ACS compared with patients with HF. Older age was associated with higher adjusted hospital mortality and 1 year mortality in each SCAI shock stage (all P < 0.05). Additive increases in both hospital mortality and 1 year mortality were observed with increasing age and SCAI shock stage.

Conclusions Age is an independent risk factor for mortality that modifies the relationship between the SCAI shock stage and mortality risk in CICU patients, providing robust risk stratification for in-hospital and 1 year mortality. Although patients with HF had a higher risk of dying, age was more strongly associated with mortality among patients with ACS.

Keywords Age; Shock; Mortality; Cardiac intensive care unit; Critical care; Cardiogenic shock; Outcomes

Received: 12 June 2020; Revised: 31 July 2020; Accepted: 17 August 2020

*Correspondence to: Jacob C. Jentzer, Department of Cardiovascular Medicine and Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: 507-255-2502; Fax: 507-255-2550. Email: jentzer.jacob@mayo.edu

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Older age is an established non-modifiable risk factor for mortality and other adverse outcomes in hospitalized patients with cardiovascular disease or critical illness, including cardiac intensive care unit (CICU) patients.\(^1\)\(^2\) Age has been integrated into multiple clinical scoring systems designed for mortality risk stratification, and higher age has consistently been associated with an increased risk of mortality in both cardiovascular and non-cardiovascular conditions.\(^1\)\(^3\)\(^-\)\(^5\) Cardiogenic shock (CS) is associated with significant morbidity and mortality, particularly among older patients.\(^5\)\(^-\)\(^8\) Among patients with CS, older age has been identified as a major risk factor for mortality and has been potentially linked with a decreased response to certain therapies.\(^9\)\(^-\)\(^15\)

Recently, the Society for Cardiovascular Angiography and Interventions (SCAI) published a CS severity classification system, allowing more consistent grading of CS acuity across stages.\(^1\)\(^6\) The SCAI shock stages classification provides robust mortality risk stratification in unselected CICU patients and patients with CS.\(^5\)\(^,\)\(^17\)\(^-\)\(^19\) One stated purpose of the SCAI shock stages classification is to standardize communication between providers to streamline inter-facility transfers in health systems utilizing the recommended “hub-and-spoke” model.\(^16\) There are few available data regarding whether age influences the severity of CS or whether age modifies outcomes across the acuity spectrum of CS. Understanding the intersection of age and shock severity for mortality risk stratification could facilitate CICU patient triage and clinical decision-making.

The aim of this study was to determine the effect of age on in-hospital and 1 year mortality in unselected CICU patients as a function of shock severity (defined by the SCAI shock stage) and to provide further insights about how older age contributes to worse outcomes.

Methods

Study population

This study was approved by the Institutional Review Board of Mayo Clinic (IRB # 16-000722) as posing minimal risk to patients and was performed under a waiver of informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki. We retrospectively analysed a previously constructed database including data from the index CICU admission of consecutive unique adult patients aged ≥18 years admitted to the CICU at Mayo Clinic Hospital, St. Mary’s Campus between 1 January 2007, and 31 December 2015.\(^1\)\(^-\)\(^6\),\(^17\),\(^18\),\(^20\)\(^-\)\(^26\) To minimize bias associated with CICU readmission, only data from the first CICU admission during the study period were analysed.

Data sources

Using the Multidisciplinary Epidemiology and Translational Research in Intensive Care Data Mart, we recorded demographic, vital signs, laboratory, clinical, and outcome data, as well as procedures and therapies performed during the CICU and hospital stay.\(^1\)\(^,\)\(^4\)\(^-\)\(^6\),\(^17\),\(^18\),\(^20\)\(^-\)\(^27\) The admission vital signs, clinical measurements, and laboratory values were defined as either the first value recorded after or closest to the index CICU admission. Vital signs were recorded every 15 min during the first hour after CICU admission. Admission diagnoses were defined as all International Classification of Diseases-9 diagnostic codes within 1 day before or after CICU admission; admission diagnoses were not mutually-exclusive.\(^5\)\(^,\)\(^6\),\(^18\),\(^21\)

Maximum vasopressor and inotrope doses during the CICU stay were quantified using the peak vasoactive-inotropic score.\(^22\) Non-cardiovascular organ failure was defined as a score ≥3 on any of the non-cardiovascular Sequential Organ Failure Assessment (SOFA) organ sub-scores on CICU Day 1.\(^21\) The Acute Physiology and Chronic Health Evaluation (APACHE) III score, APACHE IV predicted hospital mortality, and SOFA scores were automatically calculated using data from the first 24 h of CICU admission using previously validated electronic algorithms.\(^1\)\(^,\)\(^4\),\(^20\),\(^21\),\(^25\) The non-cardiovascular SOFA score was calculated by summing the other five SOFA organ sub-scores.\(^4\),\(^25\) Individual co-morbidities used to calculate the Charlson Co-morbidity Index were extracted from the medical record using a previously validated electronic algorithm.\(^28\) The Braden Skin Score at the time of CICU admission was used as a surrogate marker of frailty.\(^1\),\(^26\) When available, echocardiographic data were extracted for patients with an echocardiogram within 1 day before or after hospitalization; left ventricular systolic dysfunction (LVSD) was defined using left ventricular ejection fraction (LVEF) according to current guidelines.\(^29\)

Definition of Society for Cardiovascular Angiography and Interventions shock stages

As per our previously published definitions, we defined hypotension/tachycardia, hypoperfusion, deterioration, and refractory shock using data from CICU admission through the first 24 h in the CICU (Supporting Information, Table S2).\(^5\)\(^,\)\(^17\),\(^18\) We mapped the five SCAI shock stages with increasing severity (A through E) using combinations of these variables (Supporting Information, Table S2).\(^5\)\(^,\)\(^16\)\(^-\)\(^18\) Late deterioration was defined as an increasing number or dose of...
vasopressors after 24 h, independent of the initial SCAI shock stage.5,17,18

Statistical analysis

All-cause CICU, hospital, and 1 year mortality were determined using an electronic review of medical records for notification of patient death and last follow-up date. Mortality data were extracted from Mayo Clinic electronic databases, the state of Minnesota electronic death certificates, and the Rochester Epidemiology Project database.30 Variables of interest were compared across age groups. Categorical variables are reported as number (percentage), and the Pearson χ² test was used to compare groups; trends across age groups and SCAI stages were determined using the Cochran–Armitage trend test. Continuous variables are reported as mean (± standard deviation), and the Wilcoxon rank-sum test was used to compare groups. Odds ratio (OR) and 95% confidence interval (CI) values for hospital mortality were determined using logistic regression, before and after adjusting for gender, Charlson Co-morbidity Index, and age groups. Categorical variables were compared using the Wilcoxon rank-sum test; trends across age groups using the Wilcoxon rank-sum test. For continuous variables, data are presented as median (interquartile range), with P values representing trends across age groups using the Cochran–Armitage trend test. Continuous variables are reported as mean (± standard deviation), and the Wilcoxon rank-sum test was used to compare groups. Odds ratio (OR) and 95% confidence interval (CI) values for hospital mortality were determined using logistic regression, before and after adjusting for gender, Charlson Co-morbidity Index, and age groups. Categorical variables were compared using the Wilcoxon rank-sum test; trends across age groups using the Wilcoxon rank-sum test.

Results

Study population

The database included 10 004 unique CICU patients. The mean age was 67 ± 15 years, 3746 (37.4%) were female, 3037 (30.3%) were White race, and 1105 (85.7%) were female. For categorical variables, data are presented as number (per cent), with P values representing trends across age groups using the Cochran–Armitage trend test. For continuous variables, data are presented as median (interquartile range), with P values representing between-groups comparisons using the Wilcoxon rank-sum test.

Table 1 Baseline characteristics, co-morbidities, and admission diagnoses of the study population, divided by age group

| Demographics and outcomes | <50 (n = 1290) | 50–64 (n = 2733) | 65–79 (n = 3734) | ≥80 (n = 2257) | P value |
|---------------------------|---------------|-----------------|-----------------|---------------|---------|
| **Variables**             |               |                 |                 |               |         |
| Age (years)               | 42.6 (34.9, 47.2) | 58.5 (54.7, 61.9) | 72.6 (68.9, 76.2) | 85.3 (82.6, 88.6) | <0.001 |
| Female gender             | 464 (36%)     | 797 (29.2%)     | 1384 (37.2%)    | 1101 (48.8%)   | <0.001 |
| White race                | 1105 (85.7%)  | 2458 (89.9%)    | 3481 (93.5%)    | 2192 (97.1%)   | <0.001 |
| Body mass index           | 28.7 (24.5, 34.4) | 29.6 (25.7, 34.4) | 28.8 (25.3, 33.2) | 26.9 (23.8, 30.3) | <0.001 |
| ICU length of stay        | 1.7 (0.9, 2.8) | 1.8 (1.0, 2.9)  | 1.8 (0.9, 3.0)  | 1.7 (0.9, 2.8) | 0.0258 |
| Hospital length of stay   | 3.9 (2.3, 8.5) | 4.1 (2.5, 9)    | 4.9 (2.8, 9.6)  | 4.8 (2.8, 8)   | <0.001 |
| CICU mortality            | 32 (2.5%)     | 122 (4.5%)      | 228 (6.1%)      | 188 (8.3%)     | <0.001 |
| Hospital mortality        | 56 (4.3%)     | 196 (7.2%)      | 374 (10%)       | 282 (12.5%)    | <0.001 |
| Overall 1 year survival   | 1152 (89.3%)  | 2310 (84.5%)    | 2848 (76.5%)    | 1443 (63.9%)   | <0.001 |
| Co-morbidities            |               |                 |                 |               |         |
| Charlson Co-morbidity     | 0 (0, 2)      | 1 (0, 3)        | 2 (1, 4)        | 3 (1, 4)       | <0.001 |
| Prior myocardial infarction | 109 (8.5%)  | 449 (16.5%)     | 872 (23.5%)     | 550 (24.4%)    | <0.001 |
| Prior congestive heart failure | 169 (13.2%) | 408 (15%)       | 814 (21.9%)     | 562 (24.9%)    | <0.001 |
| Prior stroke              | 65 (5%)       | 194 (7.1%)      | 513 (13.8%)     | 457 (20.3%)    | <0.001 |
| Prior chronic kidney disease | 140 (10.0%) | 410 (15%)       | 843 (22.7%)     | 638 (28.3%)    | <0.001 |
| Prior diabetes mellitus   | 186 (14.5%)   | 715 (26.2%)     | 1294 (34.8%)    | 642 (28.5%)    | <0.001 |
| Prior cancer              | 94 (7.3%)     | 369 (13.6%)     | 926 (24.9%)     | 746 (33.1%)    | <0.001 |
| Prior lung disease        | 171 (13.4%)   | 424 (15.6%)     | 820 (22.1%)     | 529 (23.4%)    | <0.001 |
| Prior dialysis            | 76 (5.9%)     | 171 (6.3%)      | 229 (6.2%)      | 95 (4.2%)      | 0.004  |
| Admission diagnosesa      |               |                 |                 |               |         |
| Cardiac arrest            | 145 (11.4%)   | 351 (13.1%)     | 476 (12.9%)     | 221 (9.8%)     | 0.001  |
| Respiratory failure       | 210 (16.5%)   | 514 (19.1%)     | 828 (22.5%)     | 527 (23.4%)    | <0.001 |
| Congestive heart failure  | 460 (36.1%)   | 1089 (40.5%)    | 1784 (48.4%)    | 1231 (54.7%)   | <0.001 |
| Acute coronary syndrome   | 449 (35.3%)   | 1226 (45.6%)    | 1622 (44.0%)    | 970 (43.0%)    | <0.001 |
| Atrial fibrillation/supraventricular tachycardia | 232 (18.2%) | 679 (25.3%) | 1323 (35.9%) | 986 (43.8%) | <0.001 |
| Ventricular tachycardia/ventricular fibrillation | 256 (20.1%) | 459 (17.1%) | 618 (16.8%) | 275 (12.2%) | <0.001 |
| Sepsis                    | 91 (7.2%)     | 146 (5.4%)      | 219 (5.9%)      | 149 (6.6%)     | 0.13   |

CICU, cardiac intensive care unit; ICU, intensive care unit.

For categorical variables, data are presented as number (per cent), with P value representing trends across age groups using the Cochran–Armitage trend test. For continuous variables, data are presented as median (interquartile range), with P value representing between-groups comparisons using the Wilcoxon rank-sum test.

Admission diagnosis data were missing for 106 patients, and admission diagnoses are not mutually exclusive.
and 9236 were White. Admission diagnoses included heart failure (HF) in 46.1%, acute coronary syndrome (ACS) in 43.1%, CA in 12.1%, and sepsis in 6.1%. The source of admission included catheterization/procedural laboratory in 40.0%, inter-facility transfer in 27.2%, emergency department in 14.0%, hospital ward in 16.0%, and others in 2.9%. Patients were grouped based on age: <50 years, 1290 (12.9%) patients; 50–64 years, 2733 (27.3%) patients; 65–79 years, 3724 (37.2%) patients; and ≥80 years, 2257 (22.6%) patients (Table 2). Baseline characteristics (Tables 1 and 2) varied as a function of age group: older patients had more co-morbidities, higher severity of illness, more organ failure (including acute kidney injury), and different patterns of admission diagnoses and use of critical care therapies. The use of critical care therapies was higher among patients aged 50–79 years but was lower among patients ≥80 years (Table 2). Admission vital signs and laboratory variables differed across age groups (Table 2), with lower heart rate, higher systolic blood pressure, lower haemoglobin, and worse renal function among older patients. Among patients with available echocardiographic data, the prevalence of LVSD increased, and LVEF decreased, with increasing age (Table 2).

### Table 2 Baseline severity of illness and therapies and procedures of the study population, divided by age group

| Severity of illness | Age (years) | P value |
|---------------------|-------------|---------|
|                     | <50 (n = 1290) | 50–64 (n = 2733) | 65–79 (n = 3734) | ≥80 (n = 2257) |
| Braden Skin Score   | 19 (17, 21) | 18 (16, 21) | 18 (15, 20) | 17 (15, 19) | <0.001 |
| APACHE III score    | 40 (30, 54) | 48 (37, 63) | 61 (50, 75) | 70 (59, 82) | <0.001 |
| APACHE IV predicted mortality | 0.04 (0.02, 0.08) | 0.05 (0.02, 0.12) | 0.11 (0.05, 0.23) | 0.18 (0.1, 0.3) | <0.001 |
| SOFA score          | 2 (1, 4) | 2 (1, 5) | 3 (1, 5) | 3 (2, 5) | <0.001 |
| Non-cardiovascular SOFA | 1 (0, 3) | 1 (0, 3) | 2 (0, 4) | 2 (1, 4) | <0.001 |
| Single organ failure | 216 (16.7%) | 439 (16.1%) | 732 (19.7%) | 485 (21.5%) | <0.001 |
| Multi-organ failure  | 113 (8.8%) | 334 (12.2%) | 501 (13.4%) | 282 (12.5%) | 0.001 |
| SCAI shock stages   | A | B | C | D | E |
| A                 | 571 (44.2%) | 1372 (50.2%) | 1700 (45.6%) | 959 (42.5%) | <0.001 |
| B                 | 450 (34.8%) | 817 (29.9%) | 1100 (29.5%) | 631 (28%) | <0.001 |
| C                 | 185 (14.3%) | 329 (12%) | 576 (15.5%) | 485 (21.5%) | <0.001 |
| D                 | 70 (5.4%) | 199 (7.3%) | 299 (8%) | 164 (7.3%) | <0.001 |
| E                 | 14 (1%) | 16 (0.6%) | 49 (1.3%) | 18 (0.8%) | <0.001 |
| Late deterioration  | 93 (7.2%) | 227 (8.3%) | 268 (7.2%) | 120 (5.3%) | 0.001 |

### Therapies and procedures

|                    | <50 (n = 1290) | 50–64 (n = 2733) | 65–79 (n = 3734) | ≥80 (n = 2257) |
|--------------------|----------------|-----------------|-----------------|----------------|
| RBC transfusion    | 98 (7.6%) | 255 (9.3%) | 514 (13.8%) | 306 (13.6%) | <0.001 |
| Use of any ventilator | 267 (20.7%) | 704 (25.8%) | 1126 (30.2%) | 629 (27.9%) | <0.001 |
| Invasive ventilator | 182 (14.1%) | 450 (16.5%) | 635 (17.1%) | 340 (15.1%) | 0.4 |
| Noninvasive ventilator | 118 (9.2%) | 359 (13.1%) | 638 (17.1%) | 374 (16.6%) | <0.001 |
| Pulmonary artery catheter | 128 (9.9%) | 255 (9.3%) | 266 (7.1%) | 72 (3.2%) | <0.001 |
| Dialysis           | 99 (7.7%) | 185 (6.8%) | 173 (4.6%) | 30 (1.3%) | <0.001 |
| Continuous renal replacement therapy | 27 (2%) | 66 (2.4%) | 59 (1.6%) | 15 (0.7%) | <0.001 |
| Vasoactive medications | 312 (24.2%) | 736 (26.9%) | 961 (25.8%) | 459 (20.3%) | <0.001 |
| Vasopressor medications | 234 (18.2%) | 574 (21%) | 848 (22.8%) | 434 (19.2%) | 0.001 |
| Inotropic medications | 171 (13.3%) | 335 (12.3%) | 323 (8.7%) | 99 (4.4%) | <0.001 |
| Coronary angiogram  | 656 (50.8%) | 1605 (58.7%) | 2053 (55.1%) | 970 (43%) | <0.001 |
| Percutaneous coronary intervention | 334 (25.9%) | 1041 (38.1%) | 1307 (35%) | 745 (33%) | <0.001 |
| Intra-aortic balloon pump | 82 (6.4%) | 292 (10.7%) | 348 (9.3%) | 143 (6.3%) | <0.001 |
| Impella®           | 5 (0.4%) | 5 (0.2%) | 7 (0.2%) | 4 (0.2%) | 0.6 |
| ECMO               | 23 (1.8%) | 29 (1.1%) | 18 (0.5%) | 2 (0.1%) | <0.001 |
| In-hospital CPR     | 26 (2%) | 83 (3%) | 136 (3.7%) | 68 (3%) | 0.02 |
| Inpatient echocardiogram | 1028 (83.2%) | 2286 (86.7%) | 3135 (86.5%) | 1770 (80.8%) | 0.005 |
| LVEF (%)           | 53 (35.61) | 51 (34.60) | 50 (34.60) | 50 (35.62) | 0.005 |
| LVSD               | 408 (48.8%) | 988 (51.0%) | 1466 (55.2%) | 831 (52.9%) | 0.009 |
| Mild               | 150 (17.9%) | 352 (18.2%) | 465 (17.5%) | 271 (17.2%) | <0.001 |
| Moderate           | 106 (12.7%) | 302 (15.6%) | 489 (18.4%) | 334 (21.3%) | <0.001 |
| Severe             | 152 (18.2%) | 334 (17.2%) | 512 (19.3%) | 226 (14.4%) | <0.001 |

**APACHE**, Acute Physiology and Chronic Health Evaluation; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; RBC, red blood cell; SCAI, Society for Cardiovascular Angiography and Interventions; SOFA, Sequential Organ Failure Assessment.

For categorical variables, data are presented as number (per cent), with P value representing trends across age groups using the Cochran–Armitage trend test. For continuous variables, data are presented as median (interquartile range), with P value representing between-groups comparisons using the Wilcoxon rank-sum test.
### Table 3 Vital signs and laboratory values closest to cardiac intensive care unit admission as a function of age group

| Age (years) | P value |
|-------------|---------|
| <50 (n = 1290) | 50–64 (n = 2733) | 65–79 (n = 3734) | ≥80 (n = 2257) |
| **Vital signs** | | | |
| Temperature (Celsius) | 36.7 (36.5, 36.9) | 36.7 (36.4, 36.9) | 36.6 (36.4, 36.9) | 36.6 (36.4, 36.9) |
| Heart rate (b.p.m.) | 86 (72, 101) | 79 (67, 93) | 78 (66, 93) | 76 (64, 93) |
| Systolic blood pressure | 117 (102, 134) | 119 (104, 136) | 121 (105, 140) | 127 (108, 146) |
| Diastolic blood pressure | 71 (62, 82) | 71 (62, 82) | 67 (57, 77) | 65 (55, 76.2) |
| Respiratory rate (respirations per minute) | 18 (15, 21) | 17 (14, 21) | 18 (15, 21) | 18 (15, 22) |
| Shock index | 0.72 (0.6, 0.9) | 0.65 (0.5, 0.8) | 0.64 (0.5, 0.8) | 0.62 (0.5, 0.8) |
| Oxygen saturation | 98 (95, 99) | 98 (95, 99) | 97 (94, 99) | 97 (94, 99) |
| Mean arterial pressure | 82 (73, 94) | 84 (74, 95) | 81 (71, 92) | 81 (70, 93) |
| Urine output in the first 24 h (mL) | 1964 (1200, 2989) | 1915 (1175, 2823) | 1649 (1000, 2524) | 1420 (835, 2141) |
| **Laboratory values** | | | |
| Haemoglobin (g/dL) | 13 (11.2, 14.4) | 12.9 (11.2, 14.2) | 11.9 (10.4, 13.4) | 11.5 (10.1, 12.8) |
| White blood cell count (× 10^9/L) | 9.9 (7.6, 13.1) | 9.8 (7.4, 12.8) | 9.4 (7.2, 12.4) | 9.4 (7.3, 12.5) |
| Platelets (× 10^9/L) | 211 (166, 266) | 208 (166, 259) | 196 (154, 241) | 195 (153, 244) |
| Sodium (mmol/L) | 139 (135, 140) | 138 (136, 140) | 138 (136, 141) | 139 (136, 141) |
| Potassium (mmol/L) | 4.1 (3.8, 4.5) | 4.2 (3.9, 4.6) | 4.2 (3.9, 4.6) | 4.3 (3.9, 4.7) |
| Chloride (mmol/L) | 103 (100, 106) | 104 (100, 106) | 103 (100, 106) | 103 (100, 106) |
| Bicarbonate (mmol/L) | 24 (21, 26) | 24 (21, 26) | 24 (21, 26) | 24 (21, 27) |
| Anion gap | 11 (9, 14) | 11 (9, 14) | 11 (9, 14) | 11 (9, 14) |
| Blood urea nitrogen (mg/dL) | 15 (11, 21) | 18 (13, 26) | 22 (16, 34) | 26 (19, 38) |
| Creatinine (mg/dL) | 0.9 (0.7, 1.2) | 1 (0.8, 1.3) | 1.1 (0.8, 1.5) | 1.2 (0.9, 1.6) |
| Estimated GFR (MDRD) | 87.4 (64.9, 104.8) | 75.2 (52.3, 89.1) | 60.5 (40.4, 81.5) | 52.1 (35.4, 68.6) |
| Aspartate aminotransferase (U/L) | 46 (28, 111) | 49 (29, 125) | 44 (27, 100) | 43 (27, 95) |
| Alanine aminotransferase (U/L) | 38 (22, 69) | 35 (22, 66) | 30 (20, 58.2) | 26 (17, 49) |
| Lactate (mmol/L) | 1.5 (1.1, 2.8) | 1.8 (1.2, 3.1) | 1.8 (1.1, 3.2) | 1.8 (1.2, 3) |
| Arterial pH | 7.38 (7.3, 7.4) | 7.37 (7.3, 7.4) | 7.36 (7.3, 7.4) | 7.37 (7.3, 7.4) |

GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.

Data are presented as median (interquartile range), with P value representing between-groups comparisons using the Wilcoxon rank-sum test.

---

age groups (Table 2 and Supporting Information, Figure S1A), without a definite trend (P = 0.23 for trend). The use of vasoactive drugs and the peak vasoactive–inotropic score varied across age groups, without significant trends (Table 2). There was lower use of all mechanical support devices (particularly intra-aortic balloon pump and extracorporeal membrane oxygenation) and pulmonary artery catheter in patients in the older age groups (Table 2 and Supporting Information, Figure S1B). The prevalence of late deterioration varied across age groups and was lowest among patients ≥80 years (Table 1).

**Hospital mortality**

Hospital mortality occurred in 908 (9.1%) patients, including 570 (5.7%) who died in the CICU. Both CICU and hospital mortality were higher in older patients (P < 0.001 for trends). Hospital mortality rose with increasing age in each SCAI shock stage except stage D (all other P < 0.01 for trend; Figure 1). Hospital mortality rose with increasing SCAI shock stage in each age group (all P < 0.001 for trends; Figure 2). Similar findings were observed in patients with admission diagnoses of ACS (Supporting Information, Figure S2A) or HF (Supporting Information, Figure S2B). Age was significantly associated with unadjusted hospital mortality in each SCAI shock stage (all P < 0.05), and the SCAI shock stage was significantly associated with unadjusted hospital mortality in each age group (all P < 0.001). Adding age to the SCAI shock stages increased the area under the receiver-operator characteristic curve for hospital mortality (0.790 vs. 0.765, P < 0.001 by DeLong test).

After multivariable adjustment, increasing age was associated with higher hospital mortality (adjusted OR per 10 years 1.324, 95% CI 1.234–1.420, P < 0.001). After adjustment, older age remained associated with higher hospital mortality in each SCAI shock stage (all P < 0.05; Figure 2A). As shown in Supporting Information, Figure S2, each older age group was associated with incrementally higher adjusted hospital mortality than each of the younger age groups (all P < 0.05).

**One year mortality**

A total of 2251 (22.5%) patients died by 1 year (including hospital deaths), and 954 (9.5%) patients had <1 year of follow-up. One year mortality increased progressively with rising age group (Figure 3; P < 0.001 by log-rank test). Age remained associated with 1 year mortality after multivariable adjustment (adjusted HR per 10 years 1.243, 95% CI 1.200–1.288, P < 0.001). After adjustment, older age was associated with higher 1 year mortality in each SCAI shock stage (all P < 0.05; Figure 2B). Figure 4 demonstrates 1 year survival as a function of age and SCAI shock stage using the Kaplan–Meier method, showing gradations in 1 year mortality as...
either age or SCAI shock stage increased. As shown in Supporting Information, Figure S3, each older age group was associated with incrementally higher adjusted 1 year mortality than each of the younger age groups (all \( P < 0.01 \)).

### Patients with heart failure

Subgroup analysis was performed in 4564 (46.1%) patients with an admission diagnosis of HF. Both a prior history of HF and an admission diagnosis of HF became more prevalent with increasing age (Table 1). Among patients with available echocardiographic data, the prevalence of LVSD among patients with HF was 72.1%, with a median LVEF of 36% (interquartile range: 25, 55); 13.6% had mild LVSD, and the remainder had moderate or severe LVSD (Table 4). Patients with an admission diagnosis of HF were older (71.2 vs. 67.0 years, \( P < 0.001 \)) and had higher illness severity, greater use of critical care therapies, and higher length of stay (Table 4); patients with HF had higher SCAI shock stages and a higher risk of late deterioration (all \( P < 0.001 \)). Patients with HF had a higher risk of dying at all time points, accounting for 60.6% of all hospital deaths and 67.0% of all 1 year deaths. Although an admission diagnosis of HF was not
associated with hospital mortality after adjustment ($P = 0.85$), patients with HF were at higher risk of 1 year mortality (adjusted HR 1.456, 95% CI 1.321–1.606, $P < 0.001$). One year mortality by the Kaplan–Meier method increased incrementally as a function of higher SCAI shock stage and higher age among patients with HF (Supporting Information, Figure S4).

Age was more strongly associated with adjusted hospital mortality in patients with an admission diagnosis of ACS (adjusted OR per 10 years 1.589, 95% CI 1.393–1.813, $P < 0.001$) than patients with an admission diagnosis of HF (adjusted OR per 10 years 1.311, 95% CI 1.202–1.430, $P < 0.001$). Similarly, age was more strongly associated with adjusted 1 year mortality in patients with an admission diagnosis of ACS (adjusted OR per 10 years 1.506, 95% CI 1.409–1.609, $P < 0.001$) than patients with an admission diagnosis of HF (adjusted OR per 10 years 1.279, 95% CI 1.225–1.336, $P < 0.001$). SCAI shock stage was a strong ($P < 0.001$) predictor of both hospital mortality and 1 year mortality in patients with ACS or HF, although the adjusted OR/HR values were modestly higher for patients with ACS.

**Discussion**

In this analysis of 10 004 CICU patients, we demonstrated the additive effects of older age and rising shock severity on short-term and long-term mortality. Older patients had higher overall illness severity, more co-morbidities, and more critical care needs but did not have greater shock severity based on SCAI shock stage. Older patients had higher in-hospital and post-discharge mortality even after adjusting for shock severity, early non-cardiovascular organ dysfunction, and frailty. Expectedly, older individuals with more severe shock had worse outcomes compared with younger patients or those with less severe shock. We observed relevant interactions between age and SCAI shock stage, and the effect of age on adjusted mortality varied by SCAI stage. Older patients in SCAI shock stages D and E had particularly
Table 4  Baseline characteristics of patients with and without and admission diagnosis of HF

| Demographics and outcomes | Patients with HF (n = 4564) | Patients without HF (n = 5334) | P value |
|---------------------------|-----------------------------|--------------------------------|---------|
| Age (years)               | 71.2 (60.6, 80.8)           | 67.0 (55.7, 77.4)              | <0.001  |
| <50 years                 | 460 (10.1%)                 | 813 (15.2%)                    | <0.001  |
| 50–64 years               | 1089 (23.9%)                | 1598 (30.0%)                   |         |
| 65–79 years               | 1784 (39.1%)                | 1902 (35.7%)                   |         |
| ≥80 years                 | 1231 (27.0%)                | 1021 (19.1%)                   |         |
| Female gender             | 1757 (38.5%)                | 1954 (36.6%)                   | 0.06    |
| White race                | 4187 (91.7%)                | 4948 (92.8%)                   |         |
| Body mass index (kg/m²)   | 28.4 (24.7, 33.3)           | 28.4 (25.0, 32.8)              | 0.35    |
| ICU length of stay (days) | 2.0 (1.0, 3.7)              | 1.4 (0.9, 2.4)                 | <0.001  |
| Hospital length of stay (days) | 7.0 (3.9, 12.3) | 3.2 (2.1, 5.9) | <0.001 |
| CICU mortality            | 311 (6.8%)                  | 257 (4.8%)                     | <0.001  |
| Hospital mortality        | 549 (12.0%)                 | 257 (6.7%)                     | <0.001  |
| Overall 1 year survival   | 3056 (67.0%)                | 4593 (86.1%)                   | <0.001  |
| Charlson Co-morbidity Index | 2 (1, 5)                  | 1 (0, 3)                       | <0.001  |
| Prior myocardial infarction | 1098 (24.1%)              | 870 (16.4%)                    | <0.001  |
| Prior congestive heart failure | 1701 (37.4%)             | 243 (4.6%)                     | <0.001  |
| Prior stroke               | 700 (15.4%)                 | 517 (9.7%)                     | <0.001  |
| Prior chronic kidney disease | 1371 (30.1%)             | 649 (12.2%)                    | <0.001  |
| Prior diabetes mellitus    | 1615 (35.5%)                | 1199 (22.5%)                   | <0.001  |
| Prior cancer               | 1066 (23.4%)                | 1057 (19.9%)                   | <0.001  |
| Prior lung disease         | 1100 (24.2%)                | 837 (15.7%)                    | <0.001  |
| Severity of illness        |                            |                                |         |
| Braden Skin Score          | 17 (15, 20)                 | 18 (16, 20)                    | <0.001  |
| APACHE III score           | 65 (52, 80)                 | 52 (39, 52)                    | <0.001  |
| APACHE IV predicted mortality (%) | 14.1 (6.5, 29.2) | 6.4 (2.7, 14.4) | <0.001 |
| SOFA score                 | 4 (2, 6)                    | 2 (1, 4)                       | <0.001  |
| Non-cardiovascular SOFA    | 3 (1, 5)                    | 1 (0, 2)                       | <0.001  |
| Single organ failure       | 1106 (24.2%)                | 746 (14.0%)                    | <0.001  |
| Multi-organ failure        | 780 (17.1%)                 | 436 (8.2%)                     | <0.001  |
| SCAI shock stages          |                            |                                |         |
| A                          | 1675 (36.7%)                | 2871 (53.8%)                   | <0.001  |
| B                          | 1562 (34.2%)                | 1414 (26.5%)                   |         |
| C                          | 758 (16.6%)                 | 799 (15.0%)                    |         |
| D                          | 513 (11.2%)                 | 213 (4.0%)                     |         |
| E                          | 56 (1.2%)                   | 39 (0.7%)                      |         |
| Late deterioration         | 566 (12.4%)                 | 140 (2.6%)                     | <0.001  |
| Therapies and procedures   |                            |                                |         |
| RBC transfusion            | 658 (14.4%)                 | 506 (9.5%)                     | <0.001  |
| Use of any ventilator      | 1817 (39.8%)                | 884 (16.6%)                    | <0.001  |
| Invasive ventilator        | 989 (21.7%)                 | 603 (11.3%)                    | <0.001  |
| Noninvasive ventilator     | 1108 (24.3%)                | 369 (6.9%)                     | <0.001  |
| Pulmonary artery catheter  | 622 (13.6%)                 | 97 (1.8%)                      | <0.001  |
| Dialysis                   | 385 (8.4%)                  | 102 (1.9%)                     | <0.001  |
| Continuous renal replacement therapy | 139 (3.0%) | 28 (0.5%) | <0.001 |
| Vasoactive medications     | 1685 (36.9%)                | 764 (14.3%)                    | <0.001  |
| Vasopressor medications    | 1321 (28.9%)                | 750 (14.1%)                    | <0.001  |
| Inotrope medications       | 789 (17.3%)                 | 135 (2.5%)                     | <0.001  |
| Coronary angiogram         | 2070 (45.4%)                | 3133 (58.7%)                   | <0.001  |
| Percutaneous coronary intervention | 1151 (25.2%) | 2226 (41.7%) | <0.001 |
| Intra-aortic balloon pump  | 568 (12.4%)                 | 288 (5.4%)                     | <0.001  |
| Impella®                   | 16 (0.4%)                   | 5 (0.1%)                       | 0.006   |
| ECMO                       | 59 (1.3%)                   | 13 (0.2%)                      | <0.001  |
| In-hospital CPR            | 163 (3.6%)                  | 147 (2.8%)                     | 0.02    |
| Inpatient echocardiogram   | 3864 (85.5%)                | 4283 (84.2%)                   | 0.07    |
| LVEF (%)                   | 36 (25, 55)                 | 55 (48, 63)                    | <0.001  |
| LVSD                       | 2397 (72.1%)                | 1267 (35.1%)                   | <0.001  |

(Continues)
high crude in-hospital and 1 year mortality, despite age being more strongly associated with mortality in lower SCAI shock stages. This study adds to the growing body of evidence highlighting older age and greater shock severity as major mortality risk factors among CICU patients.

Age has been consistently found to be an independent risk factor for mortality in multiple prior studies of hospitalized and critically ill cardiac patients, including CICU populations, patients with CS, and patients with ACS.\(^{9,15,31–33}\) Age is a critical variable in most mortality prediction risk scores, including those specifically designed for patients with CS as well as standard scoring systems such as APACHE.\(^{1,3,11,12,20,24}\) Illness severity scores have lower discrimination of mortality in older CICU patients, raising important questions about how best to risk-stratify older CICU patients given their higher risk of adverse outcomes than younger patients.\(^1\) Even though age is an important risk factor for mortality in both ACS and HF, we unexpectedly observed that the relationship between age (and to a lesser extent SCAI shock stage) and mortality was weaker for patients with HF compared with ACS patients.\(^{24,34}\) While this could reflect the lower overall discrimination for hospital mortality that we have previously observed in CICU patients with HF (who have a higher baseline mortality risk), this could suggest that standard risk factors for mortality do not adequately categorize CICU patients with HF and imply a need to identify novel risk factors within this cohort.\(^{24,34}\) Indeed, age itself may be a less relevant risk factor in patients with HF than illness duration, co-morbidity burden, and frailty (i.e. biological age vs. chronological age).

Our study demonstrates additively higher mortality as both age and SCAI shock stage increased, contributing to the growing literature validating the SCAI shock stages paradigm for risk stratification of critically ill cardiac patients.\(^{5,17–19}\) We observed incremental increases in hospital mortality with rising age in SCAI shock stages A, B, and C, with a notable step-up in hospital mortality for patients aged ≥65 years in SCAI shock stage E. One year mortality was high for older patients with severe shock—fewer than half of SCAI shock stage D patients aged ≥50 years were alive at 1 year, as were fewer than one in five SCAI shock stage E patients aged ≥65 years. Overall, these data help to provide mortality estimates to guide triage and transfer of older CICU patients with shock, particularly in resource-limited settings.

We observed trends suggesting less aggressive care strategies among patients ≥80 years, which suggests that the application of critical care therapies in older patients may be modified by age-related co-morbidities, frailty, perceived benefits, and individual goals of care. Importantly, the efficacy of standard therapies for CS has not been systematically examined in older patients, and older age may be an exclusion criterion for advanced HF therapies. The stronger association that we observed between age and mortality for patients with ACS when compared with HF patients could reflect the effects of older age on the clinical efficacy of revascularization in ACS. Notably, a post hoc subgroup analysis of the SHOCK trial suggested a decreased benefit of early revascularization among acute myocardial infarction-related CS patients aged ≥75 years.\(^{14}\) In contrast, the majority of observational studies have demonstrated meaningful survival benefits with early revascularization and aggressive critical care therapies in older acute myocardial infarction-related CS patients attributable to their higher baseline risk.\(^{5,35,36}\) Furthermore, older patients with ACS and CS may have subtle symptoms and non-cardiac co-morbidities leading to delays in diagnosis and management with resultant worse outcomes.\(^{37}\) Despite poor outcomes, care was not necessarily futile among our older patients with severe shock, and individualized decision-making should take into account prognostically relevant factors such as organ failure severity and baseline health status.

The proposed pathophysiological basis for the relationship between age and outcomes is multifactorial, including decreased tissue regenerative capacity, limited physical reserve, co-morbidities, frailty, and psychosocial factors.\(^{1,37–39}\) Frailty has gained recent interest as a predictor of poor outcomes in hospitalized patients with cardiac disease, including CICU patients.\(^{39}\) Nguyen et al. recently demonstrated that frailty was associated with increased adverse outcomes in ACS patients.\(^{40}\) In the present study, we

### Table 4 (continued)

|               | Patients with HF (n = 4564) | Patients without HF (n = 5334) | P value |
|---------------|---------------------------|-------------------------------|---------|
| Mild          | 452 (13.6%)               | 773 (21.4%)                  |         |
| Moderate      | 655 (25.7%)               | 364 (10.1%)                  |         |
| Severe        | 1090 (32.8%)              | 130 (3.6%)                   |         |

APACHE, Acute Physiology and Chronic Health Evaluation; CICU, cardiac intensive care unit; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; HF, heart failure; ICU, intensive care unit; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; RBC, red blood cell; SCAI, Society for Cardiovascular Angiography and Interventions; SOFA, Sequential Organ Failure Assessment.

For categorical variables, data are presented as number (per cent), with P value representing trends across age groups using the Pearson χ² test. For continuous variables, data are presented as median (interquartile range), with P value representing between-groups comparisons using the Wilcoxon rank-sum test.

Note that admission diagnosis data were missing for 106 patients, who were not included in this analysis.
adjusted for the Braden Skin Score as a marker of frailty, as this has been previously demonstrated to predict worse outcomes in CICU patients.\textsuperscript{1,26} Age remained associated with mortality even after adjusting for the Braden Skin Score, which itself was a strong predictor of hospital and 1 year mortality; this implicates both frailty and other age-related factors as contributors to worse outcomes. Future studies are needed to better understand the physiological underpinnings of the relationship between age and adverse outcomes in CICU patients, accounting for frailty and patient care preferences.

**Limitations**

This study has relevant limitations that apply to similar retrospective cohort analyses, particularly the potential for the results to have been influenced by unmeasured confounding variables. The CICU population at Mayo Clinic may differ from other populations in terms of baseline demographics (particularly a low prevalence of racial and ethnic minorities), case mix, and procedure utilization; although the observed hospital mortality in our cohort was lower than some prior CICU studies, it is generally in line with other reported academic tertiary-care CICU populations.\textsuperscript{2,3,8,33,41} This was an all-comers CICU cohort including a heterogeneous group of patients with an array of admission diagnoses and a wide spectrum of illness severity including fewer than one-quarter of patients who met SCAI criteria for shock; as such, the results we observed may not apply equally to more highly selected cohorts of patients with CS. Our post-discharge mortality analysis should be considered exploratory, as the use of electronic health records rather than the more definitive National Social Security Death Index to determine patient death may underestimate post-discharge mortality by potentially failing to capture patients dying in other health systems. Perhaps the most important limitation of this analysis is the lack of available data regarding comprehensive frailty assessment, do-not-resuscitate orders, or cause of death, preventing us from providing specific insights about the manner in which age-related factors could have affected mortality.

**Conclusions**

Age and SCAI shock stage synergistically predict higher inhospital and 1 year mortality in a CICU patient population. By highlighting the very high mortality hazard faced by older patients with severe shock, this study emphasizes the need to better understand the optimal approach to shock management in this vulnerable subgroup. Our data can help to inform prognostic assessment for CS patients by providing real-world data about expected mortality risk out to 1 year as a function of age and SCAI shock stage, recognizing that decision-making regarding triage must rely on additional patient-specific factors and care preferences. Although older patients had higher measures of non-cardiovascular organ dysfunction and frailty, neither these factors nor shock severity was adequate to explain the association between age and higher mortality. The relationship between age and mortality varied as a function of admission diagnosis, emphasizing the nuances in prognostic assessment for patients with different forms of underlying cardiac disease. Further study will be required to elucidate the underlying pathophysiological mechanisms linking older age to worse outcomes in shock patients, to allow a tailored approach to therapy in this high-risk population.

**Conflict of interest**

The authors report no relevant conflicts of interest related to this research. D.A.B. has consulted for Getinge, Livanova, M3, Abiomed, Abbott, and Procyrion and has been a speaker for Novartis and Pfizer.

**Funding**

No extramural funding was involved in the conduct of this research.

**Author contributions**

All authors participated in the creation and production of this manuscript.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1.** Study definitions of hypotension, tachycardia, hypoperfusion, deterioration and refractory shock. Data from Jentzer, et al. J Am Coll Cardiol 2019.

**Table S2.** Definition of cardiogenic shock (CS) stages used in this study, based on the Society for Cardiovascular Angiography and Intervention (SCAI) consensus statement classification. Data from Jentzer, et al. J Am Coll Cardiol 2019.

**Figure S1.** Distribution of SCAI shock stage (A) and use of PAC and MCS in each age group (B).

**Figure S2.** Hospital mortality as a function of SCAI shock stage and age group in patients with an admission diagnosis of ACS (A) or HF (B).
Figure S3. Forest plot demonstrating adjusted odds ratio (OR) values for hospital mortality using multivariable logistic regression (A) and adjusted hazard ratio (HR) values for one-year mortality using Cox proportional-hazards analysis (B) for each age group compared with each other.

Figure S4. Heat map demonstrating one-year survival by the Kaplan–Meier method as a function of age group (Y axis) and SCAI shock stage (X axis) among the subgroup of patients with an admission diagnosis of HF. Darker colours represent lower survival.

References

1. Jentzer JC, Murphree DH, Wiley B, Bennett C, Goldfarb M, Keegan MT, Murphy JG, Wright RS, Barsness GW. Comparison of mortality risk prediction among patients ≥70 years versus <70 years of age in a cardiac intensive care unit. Am J Cardiol 2018; 122: 1773–1778.

2. Goldfarb M, van Diepen S, Liszkowski M, Jentzer JC, Pedraza I, Cercek B. Noncardiovascular disease and critical care delivery in a contemporary cardiac and medical intensive care unit. J Intensive Care Med 2019; 34: 537–543.

3. Bennett CE, Wright RS, Jentzer J, Gajic O, Murphree DH, Murphy JG, Mankad SV, Wiley BM, Bell MR, Barsness GW. Severity of illness assessment with application of the APACHE IV predicted mortality and outcome trends analysis in an academic cardiac intensive care unit. J Crit Care 2019; 50: 224–246.

4. Jentzer JC, Bennett C, Wiley BM, Murphree DH, Keegan MT, Gajic O, Wright RS, Barsness GW. Predictive value of the Sequential Organ Failure Assessment score for mortality in a contemporary cardiac intensive care unit population. J Am Heart Assoc 2018; 7. https://doi.org/10.1161/JAHA.117.008169

5. Jentzer JC, van Diepen S, Barsness GW, Henry TD, Menon V, Rihal CS, Naidu SS, Sanborn TA, Lowe AM, Gin K, Saucedo J, Webb JG, Menon V, Slater JN, Hochman JS, SHOCK Investigators. SHould we emergently revascularize Occluded Coronaries for cardiogenic shock? Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625–634.

6. Jentzer JC, van Diepen S, Ismail AS, Keegan MT, Morrow DA, Barsness GW, Anavekar NS. Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population. Am Heart J 2020; 224: 57–64.

7. Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis A, Granger CB, Hollegen S, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Phreaner N, Roswell RO, Schulman SP, Smilovitch A, Solomon MA, Ternus B, Tymchak W, Vinikram F, Morrow DA. Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes 2019; 12: e005618.

8. Bohula EA, Katz JN, van Diepen S, Alviar CL, Baird-Zars VM, Park JG, Barnett CF, Bhattal G, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis A, Granger CB, Hollegen S, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Phreaner N, Roswell RO, Schulman SP, Snell RJ, Solomon MA, Ternus B, Tymchak W, Vinikram F, Morrow DA, for the Critical Care Cardiology Trials Network. Demographics, care patterns, and outcomes of patients admitted to cardiac intensive care units: the Critical Care Cardiology Trials Network prospective North American multicenter registry of cardiac critical illness. JAMA Cardiol 2019; 4: 928–935.

9. Dzavik V, Sleeper LA, Cocke TP, Mosucci M, Saucedo J, Hosat S, Jiang X, Slater J, LeJemtel T, Hochman JS, SHOCK Investigators. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK trial registry. Eur Heart J 2003; 24: 828–837.

10. Acharya D. Predictors of outcomes in myocardial infarction and cardiogenic shock. Cardiol Rev 2018; 26: 255–266.

11. Harjola VP, Lassus J, Sionis A, Kober L, Zars VM, Barnett CF, Barsness GW, Henry TD, Menon V, Rihal CS, Naidu SS, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, Picard MH, Senegal MA, Boland J, Dzavik V, Thompson CR, Wong SC, Steingart R, Forman R, Ahlwardt PE, Godfrey E, Desvigne-Nickens P, LeJemtel TH SHOCK Investigators. SHould we emergently revascularize Occluded Coronaries in cardiogenic shock? Six years of the SHOCK trial registry. Cardiol Rev 2019; 27: 837–846.

12. Harjola VP, Lassus J, Sionis A, Kober L, Zars VM, Barnett CF, Barsness GW, Henry TD, Menon V, Rihal CS, Naidu SS, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, Picard MH, Senegal MA, Boland J, Dzavik V, Thompson CR, Wong SC, Steingart R, Forman R, Ahlwardt PE, Godfrey E, Desvigne-Nickens P, LeJemtel TH SHOCK Investigators. SHould we emergently revascularize Occluded Coronaries in cardiogenic shock? Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2019; 40: 625–634.

13. Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, Saucedo J, Webb JG, Menon V, Slater JN, Hochman JS, SHOCK Investigators. SHould we emergently revascularize Occluded Coronaries in cardiogenic shock? Outcome of patients aged ≥75 years in the Should we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J 2005; 149: 1128–1134.

14. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, Hollement SM, Kapur NK, O’Neill W, Ornato JP, Stelling K, Thiele H, van Diepen S, Naidu SS. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS). Am Heart J 2019; 181: 29–37.

15. Jentzer JC, Baran DA, van Diepen S, Barsness GW, Henry TD, Menon V, Naidu SS, Bell MR, Holmes DR Jr. Admission Society for Cardiovascular Angiography and Interventions shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. Am Heart J 2020; 219: 37–46.

16. Jentzer JC, Henry TD, Barsness GW, Menon V, Baran DA, van Diepen S. Influence of cardiac arrest and SCAI shock stage on cardiac intensive care unit mortality. Catheter Cardiovasc Interv 2020. https://doi.org/10.1002/ccd.28854

17. Schrage B, Dabboura S, Yan I, Hilal R, Neumann JT, Sörensen NA, Gößling A, Becher PM, Grahn H, Wagner T, Seiffert
20. Bennett CE, Wright RS, Jentzer J, Gajic O, Murphree DH, Murphy JG, Mankad SV, Wiley BM, Bell MR, Barsness GW. Severity of illness assessment with application of the APACHE IV predicted mortality and outcome trends analysis in an academic cardiac intensive care unit. J Crit Care 2018; 50: 242–246.

21. Jentzer JC, Wiley B, Bennett C, Murphree DH, Keegan MT, Gajic O, Kashani KB, Barsness GW. Early noncardiovascular organ failure and mortality in the cardiac intensive care unit. Clin Cardiol 2020; 43: 516–523.

22. Jentzer JC, Wiley B, Bennett C, Murphree DH, Keegan MT, Kashani KB, Bell MR, Barsness GW. Temporal trends and clinical outcomes associated with vasopressor and inotrope use in the cardiac intensive care unit. Shock 2020; 53: 452–459.

23. Jentzer JC, van Diepen S, Barsness GW, Katz JN, Wiley BM, Bennett CE, Mankad SV, Sinak LJ, Best PJ, Herrmann J, Jaffe AS, Murphy JG, Morrow DA, Wright RS, Bell MR, Anavekar NS. Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. Am Heart J 2019; 215: 12–19.

24. Lyle M, Wan SH, Murphree D, Bennett C, Wiley BM, Barsness G, Redfield M, Jentzer J. Predictive value of the get with the guidelines heart failure risk score in unselected cardiac intensive care unit patients. J Am Heart Assoc 2020; 9: e012439.

25. Jentzer JC, Bennett C, Wiley BM, Murphree DH, Keegan MT, Barsness GW. Predictive value of individual Sequential Organ Failure Assessment sub-scores for mortality in the cardiac intensive care unit. PLoS One 2019; 14: e0216177.

26. Jentzer JC, Anavekar NS, Brenes-Salazar JA, Wiley B, Murphree DH, Bennett C, Murphy JG, Keegan MT, Barsness GW. Admission Braden Skin Score independently predicts mortality in cardiac intensive care patients. Mayo Clin Proc 2019; 94: 1994–2003.

27. Herasevich V, Pickering BW, Dong Y, Peters SG, Gajic O. Informatics infrastructure for syndrome support, reporting, and modeling of critical illness. Mayo Clin Proc 2010; 85: 247–254.

28. Singh B, Singh A, Ahmed A, Wilson GA, Pickering BW, Herasevich V, Gajic O, Li G. Derivation and validation of automated electronic search strategies to extract Charlson comorbidities from electronic medical records. Mayo Clin Proc 2012; 87: 817–824.

29. Lang RM, Badano LP, Mor-Avi V, Afiolalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233–270.

30. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012; 87: 1202–1213.

31. Campaenile A, Castellani C, Santucci A, Anunziata R, Tutarini C, Reccia MR, del Pinto M, Verdecchia P, Cavallini C. Predictors of in-hospital and long-term mortality in unselected patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown) 2019; 20: 327–334.

32. Rarcliffe JA, Wilson E, Islam S, Platsman Z, Leou K, Williams G, Lucido D, Moustakakis E, Rachlo M, Bergmann SR. Mortality in the coronary care unit. Coron Artery Dis 2014; 25: 60–65.

33. Holland EM, Moss TJ. Acute noncardiovascular illness in the cardiac intensive care unit. J Am Coll Cardiol 2017; 69: 1999–2007.

34. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, van der Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.

35. Zeymer U, Hochadel M, Karcher AK, Thiele H, Darius H, Behrens S, Schumacher B, Ince H, Hoffmeister HM, Werner N, Zahn R, ALKK Study Group. Procedural success rates and mortality in elderly patients with percutaneous coronary intervention for cardiogenic shock. JACC Cardiovasc Interv 2019; 12: 1853–1859.

36. Rogers PA, Daye J, Huang H, Blaustein A, Virani S, Alam M, Kumar A, Paniagua D, Karter B, Bokzurt B, Ballantyne CM, Deswal A, Njeed H. Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. Int J Cardiol 2014; 172: 239–241.

37. Damlul AA, Forman DE, van Diepen S, Alexander KP, Page RL, Hummel SL, Menon V, Katz JN, Albert AM, Afiolalo J, Cohen MG. Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. Circulation 2020; 141: e6–e32.

38. Sujino Y, Tanno J, Nakano S, Funada S, Hosoi Y, Senbonmatsu T, Nishimura S. Impact of hypoalbuminemia, frailty, and body mass index on early prognosis in older patients (≥85 years) with ST-elevation myocardial infarction. J Cardiovasc Med 2015; 66: 263–268.

39. Rosenbaum AN, Naksu K, Narahacholou SM, Brenes-Salazar JA. Outcomes of no-negaritants admitted to the cardiac intensive care unit by the Elders Risk Assessment Score for long-term mortality risk stratification. Am J Cardiol 2017; 120: 1421–1426.

40. Nguyen TV, Le D, Tran KD, Bui KX, Nguyen TN. Frailty in elderly patients with acute coronary syndrome in Vietnam. Clin Interv Aging 2019; 14: 2213–2222.

41. Waton RA, Bohula EA, Gilliland TC, Sanchez PA, Berg DD, Morrow DA. Propective registry of cardiac critical illness in a modern tertiary care cardiac intensive care unit. Eur Heart J Acute Cardiovasc Care 2018; 8: 755–761.